Society of Surgical Oncology’s Post

Read this Annals of Surgical Oncology #Featured Article that reports on an externally validated delta radiomics-based model developed to predict overall survival, disease-free survival & the likelihood of achieving an R0 resection in patients with pancreatic ductal adenocarcinoma. 📃: https://ow.ly/ePWW50R9Lb0

Should we rethink the classification of G2 pancreatic neuroendocrine tumors? This study highlights the behavioral differences between G2a (Ki67 <10%) and G2b (10–20%) PanNETs. Tumors classified as G2b exhibit metastatic tendencies similar to G3, suggesting the need for distinct management approaches. Explore the implications for evolving protocols in Annals of Surgical Oncology: https://ow.ly/YwuC50UmAM4

From our special issue on ocular oncology, this brief review highlights issues with the current classification systems for intraocular retinoblastoma (ICRB and IIRC) and presents a theoretical framework for merging 2 existing classifications and subdividing the expanded group E, thereby preserving the ability to reanalyze existing published data. https://lnkd.in/ezYCHwy7 #Ophthalmology #VisionScience #OcularOncology #Retinoblastoma

This Annals of Surgical Oncology #FeaturedArticle helps bring definition to the biology of estrogen receptor-low-positive #BreastCancer. 📃: https://lnkd.in/gbmy4qMf

A recent retrospective cohort study highlights key differences in outcomes for invasive intraductal papillary mucinous neoplasms (IPMNs) compared to de novo pancreatic adenocarcinomas. Findings suggest invasive IPMNs have a better prognosis and a non-inferior response to neoadjuvant chemotherapy. Explore the full study in Annals of Surgical Oncology: https://lnkd.in/ghYCN-dd #FeaturedArticle

Integrative Medicine in Oncology, Redefining the Standard of Care https://lnkd.in/eu4KrmUE

From our special issue on ocular oncology, this article reviews current and emerging treatment options for retinoblastoma, with a focus on recent studies investigating the application of different types of nanoparticles for the diagnosis and treatment of this condition. https://lnkd.in/e827G3NC #Ophthalmology #ClinicalResearch #OcularOncology #Retinoblastoma

"Recent research shows that Peptide Receptor Radionuclide Therapy (PRRT) extends progression-free and overall survival for patients with gastroenteropancreatic neuroendocrine tumors who experience progression after surgical resection. The study highlights PRRT as an effective post-surgical strategy, offering improved outcomes compared to other therapies. Learn more in Annals of Surgical Oncology: https://lnkd.in/ghYCN-dd #FeaturedArticle

KEYNOTE-412 trial  -High risk, unresected locally advanced HNSCC -Pembrolizumab + chemoradiotherapy VS placebo + chemoradiotherapy. **Chemoradiotherapy: cisplatin (100 mg/m2) IV, every 3 weeks for two or three doses and accelerated (70 Gy / 35 fractions over 6 weeks) or standard fractionation radiotherapy (70 Gy / 35 fractions over 7 weeks).** "Pembrolizumab plus chemoradiotherapy did not significantly improve event-free survival compared with chemoradiotherapy alone in a molecularly unselected, locally advanced HNSCC population".

A picture is worth a thousand words...